C M Chresta
Overview
Explore the profile of C M Chresta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taylor M, Wappett M, Delpuech O, Brown H, Chresta C
Oncogene
. 2016 Jan;
35(33):4345-57.
PMID: 26776158
Non-small-cell lung cancer is the leading cause of cancer death worldwide and is comprised of several histological subtypes, the two most common being adenocarcinoma (AC) and squamous cell carcinoma (SCC)....
2.
MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells
Xenaki D, Eden T, Hickman J, Chresta C
Mol Pharmacol
. 2000 Dec;
59(1):135-43.
PMID: 11125034
The p53 gene in neuroblastoma tumors (NB) is rarely mutated but the protein accumulates in the cytoplasm. Because p53 can mediate the cytotoxic effects of chemotherapeutic agents, it is important...
3.
4.
Arriola E, Hickman J, Chresta C
Oncogene
. 1999 Mar;
18(7):1457-64.
PMID: 10050882
Testicular germ cell tumours are hypersentive to chemotherapy and cell lines derived from these tumours are chemosensitive in vitro. We have previously shown that these cell lines express undetectable levels...
5.
Arriola E, Lopez A, Chresta C
Oncogene
. 1999 Feb;
18(4):1081-91.
PMID: 10023685
The Mdm2 protein is frequently overexpressed in human non-seminomatous germ cell tumours and transitional carcinoma of the bladder where it may contribute to tolerance of wtp53. Mdm2 forms an autoregulatory...
6.
Chresta C, Arriola E, Hickman J
Behring Inst Mitt
. 1996 Oct;
(97):232-40.
PMID: 8950479
Cytotoxic drugs currently remain as the basis for the chemotherapy of metastatic cancer. Why they fail to kill sufficient tumour cells in the major human solid cancers, such as the...
7.
8.
Beere H, Chresta C, Hickman J
Mol Pharmacol
. 1996 May;
49(5):842-51.
PMID: 8622634
Specific inhibitors of topoisomerase II (e.g., ICRF-193, an inhibitor of the catalytic activity of topoisomerase II and etoposide that stabilizes enzyme/DNA cleavable complexes) have been used to probe the role...
9.
Chresta C, Masters J, Hickman J
Cancer Res
. 1996 Apr;
56(8):1834-41.
PMID: 8620501
Metastatic testicular cancers are curable, whereas bladder cancers and most other solid tumors are not. Cell lines derived from human testicular (GH, GCT27, and 833K) and bladder (RT4, RT112, and...
10.
Chapman R, Whetton A, Chresta C, Dive C
Mol Pharmacol
. 1995 Aug;
48(2):334-43.
PMID: 7651367
Constitutive activation of the Abelson (Abl) protein tyrosine kinase (PTK) is a causative event in chronic myeloid leukemia, where intense chemotherapy currently fails to eradicate the leukemic clone. Using a...